<p>AbbVie (紐約證券交易所：ABBV - 獲取免費報告) 在週四公佈了其財報。據 Briefing.com 報道，該公司本季度每股收益（EPS）為 2.65 美元，超過了預期的 2.57 美元，超出 0.08 美元。AbbVie 的淨利潤率為 11.02%，淨資產收益率為 179.47%。本季度該公司的營收為 144.6 億美元，高於分析師預期的 140.2 億美元。與去年同期相比，公司每股收益為 2.91 美元。本季度公司的營收同比增長了 4.3%。AbbVie 將其 2024 財年指導範圍更新為每股 10.71-10.91 美元。</p>
<h2>AbbVie 股價上漲 1.7%</h2>
<ul>
<li>Teva 製藥股票：挖掘這家仿製藥寶石的價值</li>
</ul>
<p>紐約證券交易所 ABBV 週五上漲 3.07 美元，收於 185.24 美元。該股交易量為 6,948,346 股，高於平均交易量 5,572,868 股。該公司的 50 日移動平均價格為 167.30 美元，200 日移動平均價格為 169.38 美元。該公司的市值為 3,271.1 億美元，市盈率為 55.39，PEG 比率為 2.23，β係數為 0.64。AbbVie 的 52 周最低價為 135.85 美元，52 周最高價為 186.85 美元。該公司的速動比率為 0.83，流動比率為 0.94，負債資產比率為 7.93。</p>
<h2>AbbVie 股息宣佈</h2>
<p>該公司最近宣佈了季度股息，將於 8 月 15 日（週四）支付。7 月 15 日（週一）持股的投資者將獲得 1.55 美元的股息。該股息的除息日為 7 月 15 日（週一）。這代表年化基礎上的 6.20 美元股息和 3.35% 的收益率。AbbVie 的股息支付比率（DPR）目前為 183.98%。</p>
<h2>分析師評級變動</h2>
<ul>
<li>MarketBeat 周評 - 7/1 - 7/5</li>
</ul>
<p>一些分析師最近對 ABBV 股票發表了評論。Piper Sandler Companies 在 7 月 3 日星期三的研究報告中重申了對 AbbVie 股票的 “超配” 評級，並設定了 190.00 美元的目標價。富國銀行公司將 AbbVie 股票的目標價從 200.00 美元上調至 205.00 美元，並在週五的研究報告中給予該公司 “超配” 評級。Cantor Fitzgerald 重申了對 AbbVie 股票的 “超配” 評級，並在週五的報告中將目標價定為 200.00 美元。摩根士丹利將 AbbVie 的目標價從 191.00 美元上調至 196.00 美元，並在 7 月 11 日星期四的研究報告中給予該股票 “超配” 評級。最後，巴克萊將 AbbVie 的目標價從 187.00 美元上調至 200.00 美元，並在週五的研究報告中給予該公司 “超配” 評級。兩家分析公司對該股票給予持有評級，十三家給予買入評級，一家給予強烈買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “中等買入”，共識目標價為 188.71 美元。</p>
<p><strong>獲取我們關於 ABBV 的最新研究報告</strong></p>
<h2>內部人員活動</h2>
<ul>
<li>AbbVie 股票：投資者購買的完美時機</li>
</ul>
<p>相關消息稱，董事長 Richard A. Gonzalez 於 7 月 17 日（週三）以 175.00 美元的平均價格出售了公司股票的 282,845 股。交易完成後，董事長直接持有公司股票 513,099 股，價值 89,792,325 美元。該交易已在提交給證券交易委員會的文件中披露，可通過此超鏈接獲得。公司內部人員持有公司股票的比例為 0.25%。</p>
<h2>關於 AbbVie（獲取免費報告）</h2>
<p>AbbVie Inc 在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，用於自身免疫性和腸道 Behçet 病以及膿皰病；Skyrizi 用於治療中度至重度斑塊狀銀屑病、銀屑病和克羅恩病；Rinvoq 用於治療類風濕和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸突型脊柱關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血液癌症患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血液癌症。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>最波動性股票，投資者需要了解的事項</li>
<li>3M 驚喜和復甦加速：現在投資還不算太晚</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>斯凱奇股票在消費者自由選擇領域表現強勁</li>
<li>投資旅遊股帶來的好處</li>
<li>科技股下跌，這些股票提供購買機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ Nvidia 內部人士拋售股票（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2"/></p>
<h2>現在是否值得投資 1,000 美元購買 AbbVie 股票？</h2>
<p>在考慮 AbbVie 之前，您可能想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而 AbbVie 並不在名單上。</p>
<p>儘管 AbbVie 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

艾伯維

<p>AbbVie（紐約證券交易所：ABBV）發佈了季度收益結果，超過了共識預期，並報告營收增長了 4.3%。該公司還更新了 2024 財年的指引。AbbVie 的股價在公告後上漲了 1.7%。分析師們給予該股票 “中等買入” 評級，共識目標價為 188.71 美元。董事長 Richard A. Gonzalez 出售了公司股票超過 28 萬股。AbbVie 是一家在全球開發和銷售藥品的製藥公司</p>

<p>AbbVie (NYSE:ABBV - Get Free Report) posted its earnings results on Thursday. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.08, Briefing.com reports. AbbVie had a net margin of 11.02% and a return on equity of 179.47%. The business had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.02 billion. During the same period in the prior year, the company posted $2.91 EPS. The company's revenue for the quarter was up 4.3% on a year-over-year basis. AbbVie updated its FY24 guidance to $10.71-10.91 EPS.</p>
<div class="lb-trans"><p>AbbVie (紐約證券交易所：ABBV - 獲取免費報告) 在週四公佈了其財報。據 Briefing.com 報道，該公司本季度每股收益（EPS）為 2.65 美元，超過了預期的 2.57 美元，超出 0.08 美元。AbbVie 的淨利潤率為 11.02%，淨資產收益率為 179.47%。本季度該公司的營收為 144.6 億美元，高於分析師預期的 140.2 億美元。與去年同期相比，公司每股收益為 2.91 美元。本季度公司的營收同比增長了 4.3%。AbbVie 將其 2024 財年指導範圍更新為每股 10.71-10.91 美元。</p>
</div><h2>AbbVie Stock Up 1.7 %</h2>
<ul>
<li>Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem</li>
</ul>
<div class="lb-trans"><h2>AbbVie 股價上漲 1.7%</h2>
<ul>
<li>Teva 製藥股票：挖掘這家仿製藥寶石的價值</li>
</ul>
</div><p>NYSE ABBV traded up $3.07 on Friday, hitting $185.24. 6,948,346 shares of the stock were exchanged, compared to its average volume of 5,572,868. The company has a 50-day moving average price of $167.30 and a 200-day moving average price of $169.38. The company has a market cap of $327.11 billion, a PE ratio of 55.39, a PEG ratio of 2.23 and a beta of 0.64. AbbVie has a fifty-two week low of $135.85 and a fifty-two week high of $186.85. The company has a quick ratio of 0.83, a current ratio of 0.94 and a debt-to-equity ratio of 7.93.</p>
<div class="lb-trans"><p>紐約證券交易所 ABBV 週五上漲 3.07 美元，收於 185.24 美元。該股交易量為 6,948,346 股，高於平均交易量 5,572,868 股。該公司的 50 日移動平均價格為 167.30 美元，200 日移動平均價格為 169.38 美元。該公司的市值為 3,271.1 億美元，市盈率為 55.39，PEG 比率為 2.23，β係數為 0.64。AbbVie 的 52 周最低價為 135.85 美元，52 周最高價為 186.85 美元。該公司的速動比率為 0.83，流動比率為 0.94，負債資產比率為 7.93。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<div class="lb-trans"><h2>AbbVie 股息宣佈</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Monday, July 15th will be issued a $1.55 dividend. The ex-dividend date of this dividend is Monday, July 15th. This represents a $6.20 dividend on an annualized basis and a yield of 3.35%. AbbVie's dividend payout ratio (DPR) is presently 183.98%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，將於 8 月 15 日（週四）支付。7 月 15 日（週一）持股的投資者將獲得 1.55 美元的股息。該股息的除息日為 7 月 15 日（週一）。這代表年化基礎上的 6.20 美元股息和 3.35% 的收益率。AbbVie 的股息支付比率（DPR）目前為 183.98%。</p>
</div><h2>Analyst Ratings Changes</h2>
<ul>
<li>MarketBeat Week in Review – 7/1 - 7/5</li>
</ul>
<div class="lb-trans"><h2>分析師評級變動</h2>
<ul>
<li>MarketBeat 周評 - 7/1 - 7/5</li>
</ul>
</div><p>A number of analysts have recently commented on ABBV shares. Piper Sandler Companies reissued an &#34;overweight&#34; rating and set a $190.00 target price on shares of AbbVie in a research note on Wednesday, July 3rd. Wells Fargo &amp; Company increased their price target on shares of AbbVie from $200.00 to $205.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating and issued a $200.00 price objective on shares of AbbVie in a report on Friday. Morgan Stanley increased their price objective on AbbVie from $191.00 to $196.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, July 11th. Finally, Barclays lifted their target price on AbbVie from $187.00 to $200.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $188.71.</p>
<div class="lb-trans"><p>一些分析師最近對 ABBV 股票發表了評論。Piper Sandler Companies 在 7 月 3 日星期三的研究報告中重申了對 AbbVie 股票的 “超配” 評級，並設定了 190.00 美元的目標價。富國銀行公司將 AbbVie 股票的目標價從 200.00 美元上調至 205.00 美元，並在週五的研究報告中給予該公司 “超配” 評級。Cantor Fitzgerald 重申了對 AbbVie 股票的 “超配” 評級，並在週五的報告中將目標價定為 200.00 美元。摩根士丹利將 AbbVie 的目標價從 191.00 美元上調至 196.00 美元，並在 7 月 11 日星期四的研究報告中給予該股票 “超配” 評級。最後，巴克萊將 AbbVie 的目標價從 187.00 美元上調至 200.00 美元，並在週五的研究報告中給予該公司 “超配” 評級。兩家分析公司對該股票給予持有評級，十三家給予買入評級，一家給予強烈買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “中等買入”，共識目標價為 188.71 美元。</p>
</div><p><strong>Get Our Latest Research Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 ABBV 的最新研究報告</strong></p>
</div><h2>Insider Activity</h2>
<ul>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
</ul>
<div class="lb-trans"><h2>內部人員活動</h2>
<ul>
<li>AbbVie 股票：投資者購買的完美時機</li>
</ul>
</div><p>In related news, Chairman Richard A. Gonzalez sold 282,845 shares of the business's stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $175.00, for a total value of $49,497,875.00. Following the completion of the sale, the chairman now directly owns 513,099 shares of the company's stock, valued at $89,792,325. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.25% of the company's stock.</p>
<div class="lb-trans"><p>相關消息稱，董事長 Richard A. Gonzalez 於 7 月 17 日（週三）以 175.00 美元的平均價格出售了公司股票的 282,845 股。交易完成後，董事長直接持有公司股票 513,099 股，價值 89,792,325 美元。該交易已在提交給證券交易委員會的文件中披露，可通過此超鏈接獲得。公司內部人員持有公司股票的比例為 0.25%。</p>
</div><h2>About AbbVie (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 AbbVie（獲取免費報告）</h2>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc 在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，用於自身免疫性和腸道 Behçet 病以及膿皰病；Skyrizi 用於治療中度至重度斑塊狀銀屑病、銀屑病和克羅恩病；Rinvoq 用於治療類風濕和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸突型脊柱關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血液癌症患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血液癌症。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than AbbVie</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Skechers Stock Shows Strength Among Consumer Discretionary Sector</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Tech Stocks Tumble, These Stocks Present Buying Opportunity</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>最波動性股票，投資者需要了解的事項</li>
<li>3M 驚喜和復甦加速：現在投資還不算太晚</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>斯凱奇股票在消費者自由選擇領域表現強勁</li>
<li>投資旅遊股帶來的好處</li>
<li>科技股下跌，這些股票提供購買機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Nvidia insiders dumping shares (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ Nvidia 內部人士拋售股票（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8736&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in AbbVie right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元購買 AbbVie 股票？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 AbbVie 之前，您可能想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而 AbbVie 並不在名單上。</p>
</div><p>While AbbVie currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 AbbVie 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

艾伯維（NYSE:ABBV）發佈財報結果